New molecules modulating bone metabolism: new perspectives in the treatment of osteoporosis

Title:

New molecules modulating bone metabolism: new perspectives in the treatment of osteoporosis

Creator:

Ivana Žofková and Jaroslav Blahoš

Identifier:

https://cdk.lib.cas.cz/client/handle/uuid:f503d96d-2edc-4daf-807e-71035ad67ed3
uuid:f503d96d-2edc-4daf-807e-71035ad67ed3
issn:0862-8408

Subject:

Fyziologie člověka a srovnávací fyziologie, estrogeny, parathormon, vitamin D, miRNA (nukleová kyselina), estrogens, parathormone, microRNA, bone microarchitecture, bone mineralization, RANKL, sclerostin, cathepsin K, Wnt/β-catenin, SERM, bisphosphonates, 14, and 612

Type:

article, články, journal articles, model:article, and TEXT

Format:

print, bez média, and svazek

Description:

In this review the authors outline traditional antiresorptive pharmaceuticals, such as bisphosphonates, monoclonal antibodies against RANKL, SERMs, as well as a drug with an anabolic effect on the skeleton, parathormone. However, there is also a focus on non-traditional strategies used in therapy for osteolytic diseases. The newest antiosteoporotic pharmaceuticals increase osteoblast differentiation via BMP signaling (harmine), or stimulate osteogenic differentiation of mesenchymal stem cells through Wnt/β-catenin (icarrin, isoflavonoid caviunin, or sulfasalazine). A certain promise in the treatment of osteoporosis is shown by molecules targeting non-coding microRNAs (which are critical for osteoclastogenesis) or those stimulating osteoblast activity via epigenetic mechanisms. Vitamin D metabolites have specific antiosteoporotic potencies, modulating the skeleton not only via mineralization, but markedly also through the direct effects on the bone microstructure., I. Zofkova, J. Blahos., and Obsahuje bibliografii

Language:

English

Rights:

http://creativecommons.org/publicdomain/mark/1.0/
policy:public

Source:

Physiological research | 2017 Volume:66 | Number:Suppl 3

Harvested from:

CDK

Metadata only:

false